Newsletter | July 30, 2021

07.30.21 -- Can Millennials Change Pharma Culture?

Is The Advent Of Decentralized Clinical Trials A Blessing Or A Curse?

Patients love decentralized trials, sponsors are embracing them, and clinical trial sites need to learn more. Here are some ways to adjust to this new era of clinical trials.

How A First-Time CEO Transformed Retrophin Into Travere Therapeutics

Eric Dube, Ph.D., was dubious when an executive recruiter pitched him the CEO position at previously embattled Retrophin (remember Martin Shkreli?). But he took the job in January 2019 and now has guided the $1.5 billion biopharma as it has increased sales, implemented a new diverse and inclusive culture, advanced its pipeline, and adopted a new name (Travere).

How Will We Engage The Millennials To Carry On? Or Will They Be Able To Change Pharma Culture?

See the answer from Stephen Rapundalo, Ph.D., president and CEO of MichBio.

From Academia To The Biopharma C-Suite

We thought an executive virtual roundtable topic, “From Academia To The Biopharma C-Suite,” would help you learn from these executives who took less traditional paths to becoming biopharmaceutical leaders. Perspectives are provided by Rahul Aras, Ph.D., CEO, Iterion Therapeutics, Steffen Mueller, Ph.D., cofounder and CSO, Codagenix, and Prem Premsrirut, M.D., Ph.D., CEO, Mirimus.

Web-Exclusive Content
3 Steps To Address Diversity In Clinical Trials

The COVID-19 pandemic in 2020 brought to light the significant disparities that exist in healthcare. But those same disparities also exist in the way clinical trials are structured and conducted. The Harvard Business Review recently published an article that outlines three recommendations for creating representative patient data.

July 2021 Digital Edition

Inside you will find more on:

  • Industry Research
  • Coming Out Of Stealth Mode
  • CEO Corner
  • Companies To Watch

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.